A Staphylococcus aureus clpX Mutant Used as a Unique Screening Tool to Identify Cell Wall Synthesis Inhibitors that Reverse β-Lactam Resistance in MRSA

A Staphylococcus aureus clpX Mutant Used as a Unique Screening Tool to Identify Cell Wall Synthesis Inhibitors that Reverse β-Lactam Resistance in MRSA

Staphylococcus aureus is a leading cause of bacterial infections world-wide. Staphylococcal infections are preferentially treated with β-lactam antibiotics, however, methicillin-resistant S. aureus (MRSA) strains have acquired resistance to this superior class of antibiotics. We have developed a gro...

Full description

Bibliographic Details
Main Authors: Kristoffer T. Bæk, Camilla Jensen, Maya A. Farha, Tobias K. Nielsen, Ervin Paknejadi, Viktor H. Mebus, Martin Vestergaard, Eric D. Brown, Dorte Frees
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Molecular Biosciences
Subjects:
ClpX
Staphylococcus aureus
cell wall synthesis
teichoic acid inhibitors
high-throughput screen
pathway-directed drug discovery
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.691569/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.691569/full

Similar Items